Literature DB >> 16256960

Anandamide suppression of Na+ currents in rat dorsal root ganglion neurons.

Hong Im Kim1, Tae Hoon Kim, Yong Kyoo Shin, Chung Soo Lee, Mijung Park, Jin-Ho Song.   

Abstract

Anandamide, the ethanolamide of arachidonic acid, is an endogenous cannabinoid. It is an agonist at CB1 and CB2 cannabinoid receptors as well as the vanilloid receptor, VR1. It is analgesic in inflammatory and neuropathic pain. Both central and peripheral mechanisms are considered to participate in its analgesia. Primary sensory neurons express Na+ currents that are involved in the pathogenesis of pain. We examined the effect of anandamide on tetrodotoxin-sensitive (TTX-S) and tetrodotoxin-resistant (TTX-R) Na+ currents in rat dorsal root ganglion neurons. Anandamide inhibited both Na+ currents in a concentration-dependent manner. At a membrane potential of -80 mV, the current inhibition was greater in TTX-S than TTX-R currents (K(d); 5.4 microM vs. 38.4 microM). The activation and inactivation became faster in TTX-R current but not in TTX-S current. Anandamide did not alter the activation voltage in either type of current. It, however, produced a hyperpolarizing shift of the steady-state inactivation voltage in both types of currents. The maximum availability at a large negative potential was not reduced by anandamide. Thus, anandamide seems to affect inactivated Na+ channels rather than resting channels. The inhibition of Na+ currents was not reversed by AM 251 (a CB1 antagonist), AM 630 (a CB2 antagonist) or capsazepine (a VR1 antagonist), suggestive of a direct action of anandamide on Na+ channels. The inhibition of Na+ currents in sensory neurons may contribute to the anandamide analgesia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16256960     DOI: 10.1016/j.brainres.2005.09.004

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  18 in total

Review 1.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 2.  The complications of promiscuity: endocannabinoid action and metabolism.

Authors:  S P H Alexander; D A Kendall
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

3.  Nav channel mechanosensitivity: activation and inactivation accelerate reversibly with stretch.

Authors:  Catherine E Morris; Peter F Juranka
Journal:  Biophys J       Date:  2007-05-11       Impact factor: 4.033

4.  Peripheral inflammation affects modulation of nociceptive synaptic transmission in the spinal cord induced by N-arachidonoylphosphatidylethanolamine.

Authors:  Vladimir Nerandzic; Petra Mrozkova; Pavel Adamek; Diana Spicarova; Istvan Nagy; Jiri Palecek
Journal:  Br J Pharmacol       Date:  2017-06-11       Impact factor: 8.739

5.  Inhibition of Navβ4 peptide-mediated resurgent sodium currents in Nav1.7 channels by carbamazepine, riluzole, and anandamide.

Authors:  Jonathan W Theile; Theodore R Cummins
Journal:  Mol Pharmacol       Date:  2011-07-25       Impact factor: 4.436

6.  Effects of the endogenous cannabinoid anandamide on voltage-dependent sodium and calcium channels in rat ventricular myocytes.

Authors:  Lina T Al Kury; Oleg I Voitychuk; Keun-Hang Susan Yang; Faisal T Thayyullathil; Petro Doroshenko; Ali M Ramez; Yaroslav M Shuba; Sehamuddin Galadari; Frank Christopher Howarth; Murat Oz
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

Review 7.  Endothelial atypical cannabinoid receptor: do we have enough evidence?

Authors:  Alexander I Bondarenko
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

8.  Anandamide inhibits transport-related oxygen consumption in the loop of Henle by activating CB1 receptors.

Authors:  Guillermo B Silva; Douglas K Atchison; Luis I Juncos; Néstor H García
Journal:  Am J Physiol Renal Physiol       Date:  2012-12-05

9.  The endogenous cannabinoid, anandamide, inhibits dopamine transporter function by a receptor-independent mechanism.

Authors:  Murat Oz; Vanaja Jaligam; Sehamuddin Galadari; George Petroianu; Yaroslav M Shuba; Toni S Shippenberg
Journal:  J Neurochem       Date:  2009-12-24       Impact factor: 5.372

Review 10.  Dynamic regulation of the endocannabinoid system: implications for analgesia.

Authors:  Devi Rani Sagar; A Gemma Gaw; Bright N Okine; Stephen G Woodhams; Amy Wong; David A Kendall; Victoria Chapman
Journal:  Mol Pain       Date:  2009-10-08       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.